BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006;43:661-72. [PMID: 16557537 DOI: 10.1002/hep.21146] [Cited by in Crossref: 128] [Cited by in F6Publishing: 102] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Papadopoulos VE, Skarlis C, Evangelopoulos ME, Mavragani CP. Type I interferon detection in autoimmune diseases: challenges and clinical applications. Expert Rev Clin Immunol 2021;17:883-903. [PMID: 34096436 DOI: 10.1080/1744666X.2021.1939686] [Reference Citation Analysis]
2 Troshina EA, Panfilova EA, Mikhina MS, Kim IV, Senyushkina ES, Glibka AA, Shifman BM, Larina AA, Sheremeta MS, Degtyarev MV, Rumyanstsev PO, Kuznetzov NS, Melnichenko GA, Dedov II. [Clinical practice guidelines for acute and chronic thyroiditis (excluding autoimmune thyroiditis)]. Probl Endokrinol (Mosk) 2021;67:57-83. [PMID: 34004104 DOI: 10.14341/probl12747] [Reference Citation Analysis]
3 Mo Z, Tang J, Wu Z, Chen D, Xie D, Wang P. Ulcerative colitis triggered by pegylated interferon alpha-2b in a patient with chronic hepatitis B: A case report and literature review. Liver Research 2021;5:97-101. [DOI: 10.1016/j.livres.2021.04.001] [Reference Citation Analysis]
4 Worth C, Briggs TA, Padidela R, Balmer E, Skae M. Endocrinopathies in Aicardi Goutières syndrome-A descriptive case series. Clin Case Rep 2020;8:2181-5. [PMID: 33235754 DOI: 10.1002/ccr3.3081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Lopalco G, Rigante D, Lopalco A, Emmi G, Venerito V, Vitale A, Capozio G, Denora N, Cantarini L, Iannone F. Safety of systemic treatments for Behçet's syndrome. Expert Opin Drug Saf 2020;19:1269-301. [PMID: 32883123 DOI: 10.1080/14740338.2020.1817379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Ho CW, Chen HH, Hsieh MC, Chen CC, Hsu SP, Yip HT, Kao CH. Hashimoto's thyroiditis might increase polycystic ovary syndrome and associated comorbidities risks in Asia. Ann Transl Med 2020;8:684. [PMID: 32617304 DOI: 10.21037/atm-19-4763] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Rouland A, Buffier P, Petit JM, Vergès B, Bouillet B. [Thyroiditis: What's new in 2019?]. Rev Med Interne 2020;41:390-5. [PMID: 32107053 DOI: 10.1016/j.revmed.2020.02.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Bhattacharya S, Goyal A, Kaur P, Singh R, Kalra S. Anticancer Drug-induced Thyroid Dysfunction. Eur Endocrinol 2020;16:32-9. [PMID: 32595767 DOI: 10.17925/EE.2020.16.1.32] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lowenstein A, Fainboim H, Reyes A, Lutzky C, Ameigeiras B, Schroder T, Eugenio Russmann ML. Autoimmune and non-autoimmune thyroid dysfunction in HCV infected and HCV-HIV co-infected patients before and after interferon alpha therapy: A prospective study. Endocrinol Diabetes Nutr (Engl Ed) 2020;67:263-71. [PMID: 31266712 DOI: 10.1016/j.endinu.2019.04.012] [Reference Citation Analysis]
10 Faustino LC, Lombardi A, Madrigal-Matute J, Owen RP, Libutti SK, Tomer Y. Interferon-α Triggers Autoimmune Thyroid Diseases via Lysosomal-Dependent Degradation of Thyroglobulin. J Clin Endocrinol Metab 2018;103:3678-87. [PMID: 30113675 DOI: 10.1210/jc.2018-00541] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
11 Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV Extrahepatic Manifestations. J Clin Transl Hepatol. 2019;7:172-182. [PMID: 31293918 DOI: 10.14218/jcth.2018.00049] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
12 Yao Q, An X, Zhang J, Mu K, Li L, Song R, Sun P, Zhang JA. IRF7 Gene Variations Confer Susceptibility to Autoimmune Thyroid Diseases and Graves' Ophthalmopathy. Int J Endocrinol 2019;2019:7429187. [PMID: 30774658 DOI: 10.1155/2019/7429187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Lombardi A, Tsomos E, Hammerstad SS, Tomer Y. Interferon alpha: The key trigger of type 1 diabetes. J Autoimmun. 2018;94:7-15. [PMID: 30115527 DOI: 10.1016/j.jaut.2018.08.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
14 Ali Khan W. Recombinant interferon alpha 2b in rheumatoid arthritis: good antigen for rheumatoid arthritis antibodies. Cent Eur J Immunol 2018;43:58-68. [PMID: 29736147 DOI: 10.5114/ceji.2018.74874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Chalan P, Di Dalmazi G, Pani F, De Remigis A, Corsello A, Caturegli P. Thyroid dysfunctions secondary to cancer immunotherapy. J Endocrinol Invest. 2018;41:625-638. [PMID: 29238906 DOI: 10.1007/s40618-017-0778-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
16 Bliddal S, Nielsen CH, Feldt-Rasmussen U. Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity. F1000Res 2017;6:1776. [PMID: 29043075 DOI: 10.12688/f1000research.11535.1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
17 Struja T, Kutz A, Fischli S, Meier C, Mueller B, Recher M, Schuetz P. Is Graves' disease a primary immunodeficiency? New immunological perspectives on an endocrine disease. BMC Med 2017;15:174. [PMID: 28942732 DOI: 10.1186/s12916-017-0939-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
18 Sayiner ZA, Eraydın A, Metin T, Özkaya M. Interferon alpha-induced non-immune thyrotoxicosis treated by plasmapheresis. BMJ Case Rep 2017;2017:bcr-2017-221228. [PMID: 28951513 DOI: 10.1136/bcr-2017-221228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Bliddal S, Borresen SW, Feldt-Rasmussen U. Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis. Front Endocrinol (Lausanne) 2017;8:179. [PMID: 28824542 DOI: 10.3389/fendo.2017.00179] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
20 Kundra A, Wang JC. Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review. Crit Rev Oncol Hematol. 2017;112:103-112. [PMID: 28325251 DOI: 10.1016/j.critrevonc.2017.02.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
21 Khan WA. Recombinant Interferon Alpha-2b is a High-Affinity Antigen for Type 1 Diabetes Autoantibodies. Can J Diabetes 2017;41:217-23. [PMID: 28024793 DOI: 10.1016/j.jcjd.2016.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Goyal G, Panag K, Garg R. Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy. Int J Appl Basic Med Res 2016;6:245-8. [PMID: 27857890 DOI: 10.4103/2229-516X.192587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
23 French JD, Bible K, Spitzweg C, Haugen BR, Ryder M. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol 2017;5:469-81. [PMID: 27773653 DOI: 10.1016/S2213-8587(16)30277-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
24 Hamza I, Eid Y, El-Sayed M, Marzaban R, Abdul-Kareem S. Thyroid Dysfunction in Chronic Hepatitis C Patients Treated with the Combined Pegylated Interferon-Ribavirin Therapy. J Interferon Cytokine Res 2016;36:527-33. [PMID: 27333271 DOI: 10.1089/jir.2016.0007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 54] [Article Influence: 7.0] [Reference Citation Analysis]
26 Khan WA, Qureshi JA. Increased binding of circulating systemic lupus erythematosus autoantibodies to recombinant interferon alpha 2b. APMIS 2015;123:1016-24. [DOI: 10.1111/apm.12464] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhang RW, Shao CP, Huo N, Li MR, Xi HL, Yu M, Xu XY. Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10. World J Gastroenterol 2015; 21(33): 9765-9773 [PMID: 26361424 DOI: 10.3748/wjg.v21.i33.9765] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Feldt-Rasmussen U. Increased risk of thyroid autoimmunity in rheumatoid arthritis. Endocrine 2015;50:4-5. [PMID: 26100789 DOI: 10.1007/s12020-015-0671-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
29 Lin JD, Wang YH, Liu CH, Lin YC, Lin JA, Lin YF, Tang KT, Cheng CW. Association of IRF8 gene polymorphisms with autoimmune thyroid disease. Eur J Clin Invest 2015;45:711-9. [PMID: 25989711 DOI: 10.1111/eci.12463] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
30 Narciso-Schiavon JL, Schiavon LL. Autoantibodies in chronic hepatitis C: A clinical perspective. World J Hepatol 2015; 7(8): 1074-1085 [PMID: 26052396 DOI: 10.4254/wjh.v7.i8.1074] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
31 Kaklamanos M, Thomas D, Pikazis D, Kaltsas G. Thyroid-specific changes following treatment with biological therapies in patients with rheumatic diseases. Endocrine 2015;50:146-53. [PMID: 25690756 DOI: 10.1007/s12020-015-0551-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
32 Fallahi P, Ferrari SM, Politti U, Giuggioli D, Ferri C, Antonelli A. Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection. Int J Endocrinol 2014;2014:935131. [PMID: 25374602 DOI: 10.1155/2014/935131] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
33 Stefan M, Wei C, Lombardi A, Li CW, Concepcion ES, Inabnet WB 3rd, Owen R, Zhang W, Tomer Y. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc Natl Acad Sci U S A 2014;111:12562-7. [PMID: 25122677 DOI: 10.1073/pnas.1408821111] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 6.9] [Reference Citation Analysis]
34 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. [PMID: 25032178 DOI: 10.3350/cmh.2014.20.2.89] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
35 Kozielewicz D, Zaleśna A, Dybowska D. Can pegylated interferon α 2a cause development of thyroid disorders in patients with chronic hepatitis B? Expert Opinion on Drug Safety 2014;13:1009-14. [DOI: 10.1517/14740338.2014.921156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
36 Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev 2014;13:391-7. [PMID: 24434360 DOI: 10.1016/j.autrev.2014.01.007] [Cited by in Crossref: 326] [Cited by in F6Publishing: 262] [Article Influence: 40.8] [Reference Citation Analysis]
37 Ban Y, Hirano T. Association studies of the SAS-ZFAT , IL-23R , IFIH1 and FOXP3 genes in autoimmune thyroid disease. Expert Review of Endocrinology & Metabolism 2014;4:325-31. [DOI: 10.1586/eem.09.21] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Torino F, Barnabei A, Paragliola R, Baldelli R, Appetecchia M, Corsello SM. Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid 2013;23:1345-66. [PMID: 23750887 DOI: 10.1089/thy.2013.0241] [Cited by in Crossref: 68] [Cited by in F6Publishing: 46] [Article Influence: 7.6] [Reference Citation Analysis]
39 Soldevila B, Alonso N, Martínez-Arconada MJ, Granada ML, Boada A, Vallejos V, Fraile M, Fernández-Sanmartín MA, Pujol-Borrell R, Puig-Domingo M, Sanmartí A, Martínez-Cáceres EM. Regulatory T cells and other lymphocyte subpopulations in patients with melanoma developing interferon-induced thyroiditis during high-dose interferon-α2b treatment. Clin Endocrinol (Oxf) 2013;78:621-8. [PMID: 22957689 DOI: 10.1111/cen.12036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
40 Mavragani CP, Niewold TB, Chatzigeorgiou A, Danielides S, Thomas D, Kirou KA, Kamper E, Kaltsas G, Crow MK. Increased serum type I interferon activity in organ-specific autoimmune disorders: clinical, imaging, and serological associations. Front Immunol 2013;4:238. [PMID: 23966997 DOI: 10.3389/fimmu.2013.00238] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
41 Alsabbagh ME, Eisa N, Alraiyes AH, Alraies MC. Chronic hepatitis C therapy: a rare complication revisited. BMJ Case Rep. 2013;2013:bcr2013200514. [PMID: 23893287 DOI: 10.1136/bcr-2013-200514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
42 Jadali Z. Autoimmune thyroid disorders in hepatitis C virus infection: Effect of interferon therapy. Indian J Endocrinol Metab 2013;17:69-75. [PMID: 23776855 DOI: 10.4103/2230-8210.107856] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
43 Macaluso FS, Alessi N, Cabibi D. Antimitochondrial antibody -M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C. Hepatol Res 2012;42:428-32. [PMID: 22443693 DOI: 10.1111/j.1872-034X.2011.00931.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
44 Hasham A, Zhang W, Lotay V, Haggerty S, Stefan M, Concepcion E, Dieterich DT, Tomer Y. Genetic analysis of interferon induced thyroiditis (IIT): evidence for a key role for MHC and apoptosis related genes and pathways. J Autoimmun 2013;44:61-70. [PMID: 23683877 DOI: 10.1016/j.jaut.2013.04.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
45 Hasham A, Tomer Y. Genetic and epigenetic mechanisms in thyroid autoimmunity. Immunol Res 2012;54:204-13. [PMID: 22457094 DOI: 10.1007/s12026-012-8302-x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 7.7] [Reference Citation Analysis]
46 Hammerstad SS, Jahnsen FL, Tauriainen S, Hyöty H, Paulsen T, Norheim I, Dahl-jørgensen K. Inflammation and Increased Myxovirus Resistance Protein A Expression in Thyroid Tissue in the Early Stages of Hashimoto's Thyroiditis. Thyroid 2013;23:334-41. [DOI: 10.1089/thy.2012.0264] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
47 Schwartz F, Bergmann N, Zerahn B, Faber J. Incidence rate of symptomatic painless thyroiditis presenting with thyrotoxicosis in Denmark as evaluated by consecutive thyroid scintigraphies. Scandinavian Journal of Clinical and Laboratory Investigation 2013;73:240-4. [DOI: 10.3109/00365513.2013.769623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
48 Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One. 2013;8:e55364. [PMID: 23383326 DOI: 10.1371/journal.pone.0055364] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
49 Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol 2012;2012:871401. [PMID: 22988469 DOI: 10.1155/2012/871401] [Reference Citation Analysis]
50 Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol 2012;2012:871401. [PMID: 22988469 DOI: 10.1155/2012/871401] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
51 Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol. 2012;2012:871401. [PMID: 22988469 DOI: 10.1155/2012/871401].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Vujosevic S, Tempesta D, Noventa F, Midena E, Sebastiani G. Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening. Hepatology 2012;56:455-63. [PMID: 22331668 DOI: 10.1002/hep.25654] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
53 Soldevila B, Alonso N, Martínez-Arconada MJ, Granada ML, Baía D, Vallejos V, Fraile M, Morillas RM, Planas R, Pujol-Borrell R. A prospective study of lymphocyte subpopulations and regulatory T cells in patients with chronic hepatitis C virus infection developing interferon-induced thyroiditis. Clin Endocrinol (Oxf). 2011;75:535-543. [PMID: 21592168 DOI: 10.1111/j.1365-2265.2011.04112.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
54 Kajiyama Y, Kikuchi K, Takai A, Hosoya N, Hoshino H, Hino K, Miyakawa H. B-cell-activating factor affects the occurrence of thyroid autoimmunity in chronic hepatitis C patients treated with interferon alpha. Clin Dev Immunol. 2012;2012:247973. [PMID: 22481965 DOI: 10.1155/2012/247973] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
55 Danilovic DL, Mendes-Correa MC, Chammas MC, Zambrini H, Marui S. Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin. Clinics (Sao Paulo) 2011;66:1757-63. [PMID: 22012048 DOI: 10.1590/s1807-59322011001000014] [Cited by in Crossref: 6] [Article Influence: 0.6] [Reference Citation Analysis]
56 Eschler DC, Hasham A, Tomer Y. Cutting edge: the etiology of autoimmune thyroid diseases. Clin Rev Allergy Immunol 2011;41:190-7. [PMID: 21234711 DOI: 10.1007/s12016-010-8245-8] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 6.1] [Reference Citation Analysis]
57 Trikudanathan GV, Ahmad I, Israel JL. Concurrent autoimmune hepatitis and grave's disease in hepatitis C during pegylated interferon α-2a and ribavirin therapy. Saudi J Gastroenterol 2011;17:348-52. [PMID: 21912063 DOI: 10.4103/1319-3767.84494] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
58 Babacan T, Sevinc A, Akarsu E, Balakan O. Sunitinib-Induced Autoimmune Thyroiditis in a Patient with Metastatic Renal Cell Carcinoma: A Case Report. Chemotherapy 2012;58:142-5. [DOI: 10.1159/000337086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
59 Yagyu H, Okada K, Sato S, Yamashita Y, Okada N, Osuga J, Nagasaka S, Sugano K, Ishibashi S. Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus. Diabetes Res Clin Pract. 2012;95:e52-e54. [PMID: 22154462 DOI: 10.1016/j.diabres.2011.11.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
60 Kim BK, Choi YS, Park YH, Lee SU. Interferon-alpha-induced destructive thyroiditis followed by Graves' disease in a patient with chronic hepatitis C: a case report. J Korean Med Sci 2011;26:1638-41. [PMID: 22148004 DOI: 10.3346/jkms.2011.26.12.1638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
61 Sabatier R, Eymard JC, Walz J, Deville JL, Narbonne H, Boher JM, Salem N, Marcy M, Brunelle S, Viens P. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? Ann Oncol. 2012;23:714-721. [PMID: 21653681 DOI: 10.1093/annonc/mdr275] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
62 Akeno N, Smith EP, Stefan M, Huber AK, Zhang W, Keddache M, Tomer Y. IFN-α mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. J Immunol 2011;186:4693-706. [PMID: 21402899 DOI: 10.4049/jimmunol.1002631] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
63 Ferenci P. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future. Expert Opin Drug Saf. 2011;10:529-544. [PMID: 21345149 DOI: 10.1517/14740338.2011.555079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
64 Nonchev BI. Cases of interferon-alpha and interferon-beta-induced thyroiditis. Folia Med (Plovdiv) 2010;52:5-12. [PMID: 21053668 DOI: 10.2478/v10153-010-0001-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
65 Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun. 2010;34:J322-J326. [PMID: 20022216 DOI: 10.1016/j.jaut.2009.11.008] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 6.4] [Reference Citation Analysis]
66 Lee YN, Jeong SW, Lim JH, Ryu YS, Jeon SR, Kim SK, Jang JY, Kim YS, Kim BS, Roh MO. [Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C]. Korean J Hepatol. 2010;16:187-191. [PMID: 20606504 DOI: 10.3350/kjhep.2010.16.2.187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Barbesino G. Drugs Affecting Thyroid Function. Thyroid 2010;20:763-70. [DOI: 10.1089/thy.2010.1635] [Cited by in Crossref: 91] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
68 Santos SRX, Ferreira MS, Borges AS, de Melo Costa Pinto R, Pereira Mendonça Fernandes ML, Jorge PT. Thyroid Disorders in Hepatitis C Patients Treated or Not With α-Interferon and Ribavirin: . The Endocrinologist 2010;20:122-4. [DOI: 10.1097/ten.0b013e3181dfcb01] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
69 Biggioggero M, Gabbriellini L, Meroni PL. Type I interferon therapy and its role in autoimmunity. Autoimmunity 2010;43:248-54. [DOI: 10.3109/08916930903510971] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
70 Kong YC, Wei WZ, Tomer Y. Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci 2010;1183:222-36. [PMID: 20146718 DOI: 10.1111/j.1749-6632.2009.05138.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
71 Menconi F, Hasham A, Tomer Y. Environmental triggers of thyroiditis: hepatitis C and interferon-α. J Endocrinol Invest 2011;34:78-84. [PMID: 21297381 DOI: 10.1007/BF03346699] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
72 Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 2009;23:703-12. [PMID: 19942147 DOI: 10.1016/j.beem.2009.07.004] [Cited by in Crossref: 60] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
73 Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 2009;23:713-22. [PMID: 19942148 DOI: 10.1016/j.beem.2009.08.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
74 Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H. Dual onset of type 1 diabetes mellitus and Graves’ disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Diabetes Res Clin Pract. 2009;86:e19-e21. [PMID: 19744739 DOI: 10.1016/j.diabres.2009.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
75 Tran HA, Reeves GE. The Spectrum of Autoimmune Thyroid Disease in the Short to Medium Term Following Interferon-alpha Therapy for Chronic Hepatitis C. Int J Endocrinol 2009;2009:241786. [PMID: 19946425 DOI: 10.1155/2009/241786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
76 Abellán Galiana P, Pérez-Lázaro A, Aguilera Sancho-Tello V, Merino Torres JF, Berenguer Haym M, Piñón Sellés F. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C]. Endocrinol Nutr 2009;56:136-9. [PMID: 19627727 DOI: 10.1016/S1575-0922(09)70844-7] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
77 Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun 2009;32:231-9. [PMID: 19307103 DOI: 10.1016/j.jaut.2009.02.007] [Cited by in Crossref: 193] [Cited by in F6Publishing: 166] [Article Influence: 14.8] [Reference Citation Analysis]
78 Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009;6:219-228. [PMID: 19333228 DOI: 10.1038/nrclinonc.2009.4] [Cited by in Crossref: 132] [Cited by in F6Publishing: 117] [Article Influence: 10.2] [Reference Citation Analysis]
79 Sarzi-puttini P, Doria A. Organ specific-autoantibodies: Their role as markers and predictors of disease: Editorial. Autoimmunity 2009;41:1-10. [DOI: 10.1080/08916930701619136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
80 Daniel AL, Houlihan JL, Blum JS, Walsh JP. Type B insulin resistance developing during interferon-alpha therapy. Endocr Pract 2009;15:153-7. [PMID: 19289328 DOI: 10.4158/EP.15.2.153] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
81 Vezali E, Elefsiniotis I, Mihas C, Konstantinou E, Saroglou G. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related? J Gastroenterol Hepatol 2009;24:1024-9. [PMID: 19383078 DOI: 10.1111/j.1440-1746.2009.05812.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
82 Stübgen J. Interferon alpha and neuromuscular disorders. Journal of Neuroimmunology 2009;207:3-17. [DOI: 10.1016/j.jneuroim.2008.12.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
83 Gelu-Simeon M, Burlaud A, Young J, Pelletier G, Buffet C. Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World J Gastroenterol 2009; 15(3): 328-333 [PMID: 19140232 DOI: 10.3748/wjg.15.328] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
84 Marx J, Schwenger V, Blank N, Stremmel W, Encke J. [Hemoptysis and acute renal failure in a 29-year-old patient with chronic hepatitis C infection]. Internist (Berl) 2008;49:1120-5. [PMID: 18604512 DOI: 10.1007/s00108-008-2099-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
85 Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. J Viral Hepat 2009;16:168-77. [PMID: 19175874 DOI: 10.1111/j.1365-2893.2008.01059.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
86 Pordeus V, Szyper-Kravitz M, Levy RA, Vaz NM, Shoenfeld Y. Infections and autoimmunity: a panorama. Clin Rev Allergy Immunol. 2008;34:283-299. [PMID: 18231878 DOI: 10.1007/s12016-007-8048-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
87 Tran H, Reeves G, Jones T. The natural history of interferon- 2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection. QJM 2008;102:117-22. [DOI: 10.1093/qjmed/hcn150] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
88 Akeno N, Blackard JT, Tomer Y. HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. J Autoimmun. 2008;31:339-344. [PMID: 18799285 DOI: 10.1016/j.jaut.2008.08.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
89 Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf). 2008;69:669-672. [PMID: 18394019 DOI: 10.1111/j.1365-2265.2008.03253.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 62] [Article Influence: 5.6] [Reference Citation Analysis]
90 Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. 2007;36:1051-1066; x-xi. [PMID: 17983936 DOI: 10.1016/j.ecl.2007.07.001] [Cited by in Crossref: 92] [Cited by in F6Publishing: 79] [Article Influence: 6.6] [Reference Citation Analysis]
91 Mittra ES, Niederkohr RD, Rodriguez C, El-maghraby T, Mcdougall IR. Uncommon Causes of Thyrotoxicosis. J Nucl Med 2008;49:265-78. [DOI: 10.2967/jnumed.107.041202] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
92 Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, Kirkwood JM. Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion. Cancer 2008;112:982-94. [DOI: 10.1002/cncr.23251] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 5.4] [Reference Citation Analysis]
93 Jacobson EM, Tomer Y. The genetic basis of thyroid autoimmunity. Thyroid 2007;17:949-61. [PMID: 17824829 DOI: 10.1089/thy.2007.0153] [Cited by in Crossref: 100] [Cited by in F6Publishing: 80] [Article Influence: 6.7] [Reference Citation Analysis]
94 Zhao ZF, Cui B, Chen HY, Wang S, Li I, Gu XJ, Qi L, Li XY, Ning G, Zhao YJ. The A946T polymorphism in the interferon induced helicase gene does not confer susceptibility to Graves' disease in Chinese population. Endocrine 2007;32:143-7. [PMID: 18026693 DOI: 10.1007/s12020-007-9024-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
95 Hoffmann CJ, Brown TT. Thyroid function abnormalities in HIV-infected patients. Clin Infect Dis 2007;45:488-94. [PMID: 17638201 DOI: 10.1086/519978] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 4.1] [Reference Citation Analysis]
96 Jacobson EM, Tomer Y. The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. J Autoimmun 2007;28:85-98. [PMID: 17369021 DOI: 10.1016/j.jaut.2007.02.006] [Cited by in Crossref: 130] [Cited by in F6Publishing: 115] [Article Influence: 8.7] [Reference Citation Analysis]
97 Caturegli P, Kimura H, Rocchi R, Rose NR. Autoimmune thyroid diseases. Curr Opin Rheumatol 2007;19:44-8. [PMID: 17143095 DOI: 10.1097/BOR.0b013e3280113d1a] [Cited by in Crossref: 90] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
98 Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol. 2007;19:61-66. [PMID: 17143098 DOI: 10.1097/bor.0b013e328010c547] [Cited by in Crossref: 59] [Cited by in F6Publishing: 18] [Article Influence: 3.9] [Reference Citation Analysis]
99 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
100 Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer 2007;121:2562-6. [DOI: 10.1002/ijc.22951] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
101 . Bibliography. Current world literature. Vasculitis syndromes. Curr Opin Rheumatol 2007;19:81-5. [PMID: 17143101 DOI: 10.1097/BOR.0b013e32801437a8] [Reference Citation Analysis]
102 Gehring S, Kullmer U, Koeppelmann S, Gerner P, Wintermeyer P, Wirth S. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-α. World J Gastroenterol 2006; 12(36): 5787-5792 [PMID: 17007043 DOI: 10.3748/wjg.v12.i36.5787] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]